Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105

americanpharmaceuticalreviewFebruary 20, 2019

Tag: InhibRx , INBRX-105 , protein engineering , antibody therapeutic

PharmaSources Customer Service